A Phase 1 interventional study of lenalidomide and lenalidomide in Chronic Lymphocytic Leukemia and Leukemia, B-Cell, Chronic, sponsored by Celgene. Completed at 35 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-11-08.
Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 78 studies testing lenalidomide in Leukemia, Lymphocytic, Chronic, B-Cell — 1 open to participants now, 5 under way, none of them phase 3. Lenalidomide · Leukemia, Lymphocytic, Chronic, B-Cell.
Among the 78 studies testing lenalidomide in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 14th largest by enrollment of the 77 interventional ones that give a count, is the only one that started in 2006, is one of 19 in phase 1, and was the 4th registered.
2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.
Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →1 of the 78 studies testing lenalidomide in Leukemia, Lymphocytic, Chronic, B-Cell is open now, in 1 country. Recruiting first, the newest first:
Vitebsk Regional Clinical Cancer Centre · Sites in Belarus
Ages 18+
By country, each count listing its studies:
Lenalidomide: first FDA approval 2005 (REVLIMID), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
78 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 32 · Phase 2 55 · Phase 3 3
First in 2002; this study’s year is marked. 1 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 52 is above the median of 39 across 1,603 interventional studies indexed under Leukemia, Lymphocytic, Chronic, B-Cell.
Median enrollment 29 across the 77 interventional studies. Of the 65 that completed or were terminated, 41 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 78 have an industry lead sponsor. The 10 most frequent:
This study is registered under Celgene, one of the names counted as Bristol-Myers Squibb. Under that name alone:
Celgene is the lead sponsor of 428 studies on the registry; 12 are open to participants now.
Of its 104 completed or terminated interventional studies of FDA-regulated products, 30 (29%) have results posted.
25 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Bristol-Myers Squibb: 1 open now, 3 under way, none of them phase 3. Of 19 finished, 6 (32%) have results posted.
Among the 25 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Bristol-Myers Squibb, this one is the 10th largest by enrollment of the 21 interventional ones that give a count, is the only one that started in 2006, is one of 12 in phase 1, and was the 1st registered.
Bristol-Myers Squibb’s Leukemia, Lymphocytic, Chronic, B-Cell studies by the year they started, since 2006.
None of the studies under way reaches primary completion within a year.
Among the 78 studies testing lenalidomide in Leukemia, Lymphocytic, Chronic, B-Cell, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Bristol-Myers Squibb’s 25 in Leukemia, Lymphocytic, Chronic, B-Cell:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety of lenalidomide and to define the maximum tolerated escalation dose level (MTEDL) when administered by a stepwise dose-escalation schedule in subjects with relapsed or refractory B-cell CLL.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
escalate up to 5 mg once daily / 28-day cycle
Drug: lenalidomide
escalate up to 10 mg once daily / 28-day cycle
Drug: lenalidomide
escalate up to 15 mg once daily / 28-day cycle
Drug: lenalidomide
escalate up to 20 mg once daily / 28-day cycle
Drug: lenalidomide
escalate up to 25 mg once daily / 28-day cycle
Drug: lenalidomide
Also known as: Revlimid, CC-5013
Also known as: Revlimid, CC-5013
Also known as: Revlimid, CC-5013
Also known as: Revlimid, CC-5013
Also known as: Revlimid, CC-5013
Safety
Time frame: February 2010
Response
Time frame: February 2010
Duration of response
Time frame: February 2010
Time to response
Time frame: February 2010
Progression free survival
Time frame: February 2010
Overall survival
Time frame: February 2010
Absolute lymphocyte count
Time frame: February 2010
Evaluation of minimal residual disease (MRD) by flow cytometry
Time frame: February 2010
Ran from Dec 2006 to primary completion in Feb 2010, 38 months.
Of 84 industry-sponsored phase 1 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 73. This study's 38 months is below that.
Counting every sponsor, half of 180 studies reached it within 56 months; a quarter within 39 and three quarters within 86.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lenalidomide
Leukemia, Lymphocytic, Chronic, B-Cell →